12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RG1068: Preliminary Phase III data

Preliminary safety data from a U.S. and Canadian Phase III trial in 258 patients showed that there were no serious adverse events (SAEs) reported in patients who received RG1068 in conjunction with MRI of the pancreas vs. 68...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >